Enhanced permeability and retention effect for selective targeting of anticancer nanomedicine: Are we there yet?

Drug Discovery Today: Technologies

Volumn 9, Issue 2, 2012, Pages

  Greish, Khaled ^a,b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b Suez Canal University Faculty of Medicine   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ANTINEOPLASTIC AGENT; CYTOKINE; NANOCARRIER; TOLL LIKE RECEPTOR 4; VASCULOTROPIN; ZINOSTATIN MALEIC ACID STYRENE COPOLYMER;

ARTICLE; BIOCOMPATIBILITY; BLOOD VESSEL PERMEABILITY; CANCER CHEMOTHERAPY; CANCER TISSUE; CELL INTERACTION; DRUG ACTIVITY; DRUG DESIGN; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG RELEASE; DRUG RETENTION; DRUG TARGETING; DRUG UPTAKE; ENHANCED PERMEABILITY AND RETENTION EFFECT; HUMAN; INTERNALIZATION; LIVER CELL CARCINOMA; NANOMEDICINE; NANOTECHNOLOGY; TARGET CELL DESTRUCTION; TISSUE PRESSURE; TUMOR VASCULARIZATION;

EID: 84873080958     PISSN: None     EISSN: 17406749     Source Type: Journal    
DOI: 10.1016/j.ddtec.2011.11.010     Document Type: Review

References (40)

1. Matsumura, Y. and Maeda, H. (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46 (Pt 1), 6387-6392
2. Matsumura, Y. et al. (1991) Kinin-generating cascade in advanced cancer patients and in vitro study. Jpn. J. Cancer Res. 82, 732-741
3. Noguchi, R. et al. (2003) Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis. Clin. Cancer Res. 9 (Pt 1), 6038-6045
4. Noguchi, Y. et al. (1998) Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn. J. Cancer Res. 89, 307-314
5. Ohkouchi, K. et al. (1990) Disposition of anticancer drugs after bolus arterial administration in a tissue-isolated tumor perfusion system. Cancer Res. 50, 1640-1644
6. Folkman, J. (1971) Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182-1186
7. Folkman, J. et al. (1971) Isolation of a tumor factor responsible for angiogenesis. J. Exp. Med. 133, 275-288
8. Peterson, H.I. and Appelgren, K.L. (1973) Experimental studies on the uptake and rentention of labelled proteins in a rat tumor. Eur. J. Cancer 9, 543-547
9. Iwai, K. et al. (1984) Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image. Cancer Res. 44, 2115-2121
10. Konno, T. et al. (1984) Selective targeting of anti-cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium. Cancer 54, 2367-2374
11. Maeda, H. et al. (1988) Purification and identification of [hydroxyprolyl3]bradykinin in ascitic fluid from a patient with gastric cancer. J. Biol. Chem. 263, 16051-16054
12. Matsumura, Y. et al. (1988) Involvement of the kinin-generating cascade in enhanced vascular permeability in tumor tissue. Jpn. J. Cancer Res. 79, 1327-1334
13. Li, C.J. et al. (1993) Augmentation of tumor delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure. Br. J. Cancer 67, 975-980
14. Maeda, K. et al. (1995) Tumor angiogenesis as a predictor of recurrence in gastric carcinoma. J. Clin. Oncol. 13, 477-481
15. Seymour, L.W. et al. (1995) Influence of molecular weight on passive tumor accumulation of a soluble macromolecular drug carrier. Eur. J. Cancer 31A, 766-770
16. Doi, K. et al. (1996) Excessive production of nitric oxide in rat solid tumor and its implication in rapid tumor growth. Cancer 77 (Suppl.), 1598-1604
17. Maeda, H. et al. (1996) Bradykinin and nitric oxide in infectious disease and cancer. Immunopharmacology 33, 222-230
18. Wu, J. et al. (1998) Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. Cancer Res. 58, 159-165
19. Doi, K. et al. (1999) Induction of haem oxygenase-1 nitric oxide and ischaemia in experimental solid tumors and implications for tumor growth. Br. J. Cancer 80, 1945-1954
20. Hori, K. et al. (2000) Tumor-selective blood flow decrease induced by an angiotensin converting enzyme inhibitor, temocapril hydrochloride. Jpn. J. Cancer Res. 91, 261-269
21. Okamoto, T. et al. (2001) Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation. J. Biol. Chem. 276, 29596-29602
22. Wu, J. et al. (2001) Enhanced vascular permeability in solid tumor involving peroxynitrite and matrix metalloproteinases. Jpn. J. Cancer Res. 92, 439-451
23. Greish, K. et al. (2003) Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumor targeting. Clin. Pharmacokinet. 42, 1089-1105
24. Tanaka, S. et al. (2003) Modulation of tumor-selective vascular blood flow and extravasation by the stable prostaglandin 12 analogue beraprost sodium. J. Drug Target. 11, 45-52
25. Greish, K. (2007) Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J. Drug Target. 15, 457-464
26. Folkman, J. (1990) What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 82, 4-6
27. Pepper, M.S. (2001) Lymphangiogenesis and tumor metastasis: myth or reality? Clin. Cancer Res. 7, 462-468
28. Padera, T.P. et al. (2002) Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 296, 1883-1886
29. Berger, D.P. et al. (1995) Vascular endothelial growth factor (VEGF) mRNA expression in human tumor models of different histologies. Ann. Oncol. 6, 817-825
30. Bachem, M.G. et al. (2005) Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology 128, 907-921
31. West, G.W. et al. (1980) Limited penetration of methotrexate into human osteosarcoma spheroids as a proposed model for solid tumor resistance to adjuvant chemotherapy. Cancer Res. 40, 3665-3668
32. Boucher, Y. et al. (1990) Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res. 50, 4478-4484
33. Greish, K. et al. (2004) SMA-doxorubicin, a new polymeric micellar drug for effective targeting to solid tumors. J. Control. Release 97, 219-230
34. Wisse, E. et al. (2008) The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer. Gene Ther. 15, 1193-1199
35. Uchino, H. et al. (2005) Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. Br. J. Cancer 93, 678-687
36. Zaki, N.M. and Tirelli, N. (2010) Gateways for the intracellular access of nanocarriers: a review of receptor-mediated endocytosis mechanisms and of strategies in receptor targeting. Expert Opin. Drug Deliv. 7, 895-913
37. Yu, T. et al. (2011) Impact of silica nanoparticle design on cellular toxicity and hemolytic activity. ACS nano 5, 5717-5728
38. Bae, Y.H. and Park, K. (2011) Targeted drug delivery to tumors: myths, reality and possibility. J. Control. Release 153, 198-205
39. Kedmi, R. et al. (2010) The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials 31, 6867-6875
40. Kao, W.J. and Lee, D. (2001) In vivo modulation of host response and macrophage behavior by polymer networks grafted with fibronectinderived biomimetic oligopeptides: the role of RGD and PHSRN domains. Biomaterials 22, 2901-2909